EntryPoint Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

EntryPoint Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60,573	Closed	-$490K	–	663
2025 Q2	$490K	Buy	60,573 +10,043	+20%	+$75.7K	0.25%	105
2025 Q1	$423K	Buy	+50,530	New	+$422K	0.19%	164
2024 Q4	–	Sell	-12,725	Closed	-$106K	–	706
2024 Q3	$106K	Sell	12,725 -5,286	-29%	-$41.3K	0.06%	552
2024 Q2	$114K	Buy	+18,011	New	+$114K	0.05%	743

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

EntryPoint Capital's AMRX Position: Q3 2025 in Review

EntryPoint Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 60,573 shares — an estimated $490K sold.

EntryPoint Capital first reported a position in AMRX in Q2 2024 and held it in 4 quarters. The position peaked at $490K in Q2 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

EntryPoint Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 60,573 Amneal Pharmaceuticals shares in Q3 2025, an estimated $490K.
EntryPoint Capital first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 4 quarters.
EntryPoint Capital's Amneal Pharmaceuticals position peaked at $490K in Q2 2025.
248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.